Core Insights - Ocugen, Inc. is set to host a conference call and live webcast on March 24, 2026, to discuss the full data set from the Phase 2 ArMaDa clinical trial evaluating OCU410 for geographic atrophy, a late-stage dry age-related macular degeneration [1] Group 1: Company Overview - Ocugen, Inc. is a biotechnology leader specializing in gene therapies for blindness diseases, utilizing a modifier gene therapy platform that addresses complex diseases caused by imbalances in multiple gene networks [3] - The company is developing programs for inherited retinal diseases and blindness diseases affecting millions globally, including retinitis pigmentosa, Stargardt disease, and geographic atrophy [3] Group 2: Conference Details - Key opinion leaders participating in the webcast include Dr. Victor H. Gonzalez and Dr. Syed M. Shah, who will answer questions during the event [2] - Attendees can join the call using specific dial-in numbers for U.S. and international callers, with a conference ID provided for access [2] - A replay of the call and archived webcast will be available on the Ocugen investor site following the event [2]

Financial Data and Key Metrics Changes - Research and development expenses for Q4 2025 were $10.7 million, up from $8.3 million in Q4 2024, indicating a year-over-year increase of approximately 29% [22] - General and administrative expenses for Q4 2025 were $6.1 million, slightly down from $6.3 million in Q4 2024 [22] - The net loss per common share for Q4 2025 was $0.06, compared to a net loss of $0.05 per common share in Q4 2024 [22] - For the full year 2025, research and development expenses totaled $39.8 million, up from $32.1 million in 2024, representing a 24% increase [23] - General and administrative expenses for the full year 2025 were $27.6 million, compared to $26.7 million in 2024 [23] - The net loss per common share for the full year 2025 was $0.23, compared to $0.20 in 2024 [23] - Current cash and cash equivalents extend the runway into Q4 2026, with a recent raise of $22.5 million through a direct offering [23][24] Business Line Data and Key Metrics Changes - Enrollment for the OCU400 phase III liMeliGhT trial is complete, with top-line data expected in Q1 2027 [7] - The OCU400 trial enrolled 140 patients, with a primary endpoint focused on visual function improvement over 12 months [7] - Positive long-term data from the OCU400 phase I/II trial showed a sustained two-line gain in low luminance visual acuity [8] - OCU410ST is targeting over 1,200 mutations associated with Stargardt disease, with phase II/III data anticipated in Q2 2027 [10] - OCU410 demonstrated a 46% reduction in lesion growth at 12 months, significantly outperforming existing therapies [16] Market Data and Key Metrics Changes - The OCU400 program targets a broader patient population, addressing 98%-99% of retinitis pigmentosa patients compared to existing therapies that only target RPE65 mutations [6] - The OCU410 program addresses a significant market opportunity with approximately 2-3 million geographic atrophy patients in the U.S. and Europe combined [15] - The OCU410ST program has received Rare Pediatric Disease Designation, enhancing its regulatory positioning [11] Company Strategy and Development Direction - The company aims to file three Biologics License Applications (BLAs) in the next three years, with a focus on transitioning into a commercial-stage company [4][18] - Regional partnerships are being pursued to maximize patient reach while retaining commercial rights in larger markets [9] - The company is strengthening its leadership team to support its transition towards regulatory approvals and commercialization [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting timelines for clinical trials and regulatory submissions, emphasizing the transformative year of 2025 [4][21] - The company is focused on addressing significant unmet medical needs in the gene therapy space, particularly for blindness diseases [4][18] - Management highlighted the importance of upcoming data releases and milestones in 2026, which are expected to drive the company's growth [18][85] Other Important Information - The company has established Ocucelix as a wholly-owned subsidiary for regenerative cell therapy assets, aiming for independence through financing [18] - The company is actively working on its inhaled vaccine candidate, OCU500, with a phase I trial expected to start in Q2 2026 [18] Q&A Session Summary Question: Confidence in data turnaround for the liMeliGhT study - Management expressed confidence in meeting the timeline for releasing top-line data in Q1 2027 [26][28] Question: Modifications for the navigation assessment course - The primary metric for RP was chosen for its sensitivity and specificity, validated by FDA approval [28][29] Question: Impact of other therapies on OCU410ST - Management believes OCU410ST will set the standard of care, regardless of other therapies entering the market [30][32] Question: FDA feedback on CMC part of the filing - CMC feedback is expected to be received after the final clinical module is filed [41] Question: Commercial value of the Ellipsoid Zone as an endpoint - The Ellipsoid Zone is gaining traction among clinicians and may provide meaningful information for commercial claims [46][48] Question: Characteristics of responders in the OCU410 program - Baseline characteristics were uniform across groups, with no unique criteria identified yet [80][82]

Core Insights - Ocugen, Inc. reported transformative developments in 2025, including advancements in gene therapy programs, licensing agreements, and leadership appointments, positioning the company for future growth and BLA filings [2][9] Financial Performance - For Q4 2025, research and development expenses were $10.7 million, up from $8.3 million in Q4 2024, while general and administrative expenses slightly decreased to $6.1 million from $6.3 million [15] - The net loss per common share for Q4 2025 was $0.06, compared to a loss of $0.05 in Q4 2024 [15] - For the full year 2025, research and development expenses totaled $39.8 million, an increase from $32.1 million in 2024, and the net loss per common share was $0.23, compared to $0.20 in 2024 [15] Clinical Trials and Developments - Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa is complete, with topline data expected in Q1 2027, supporting a potential BLA filing [2][4] - The OCU410ST Phase 2/3 GARDian clinical trial for Stargardt disease is ahead of schedule, with interim data expected in Q3 2026 [3][11] - Preliminary data from the Phase 2 ArMaDa clinical trial for OCU410 showed a 46% reduction in lesion growth at 12 months, indicating potential effectiveness in treating geographic atrophy [4][5] Market Opportunities - OCU410 targets a significant market with approximately 2 to 3 million geographic atrophy patients in the U.S. and Europe, addressing a critical unmet medical need [7] - The licensing agreement with Kwangdong Pharmaceutical for OCU400's rights in Korea is part of a strategic partnership approach, enhancing Ocugen's business development strategy [7] Cash Position and Funding - As of December 31, 2025, Ocugen had $18.9 million in cash and restricted cash, down from $58.8 million in 2024, with additional funding secured through a $22.5 million offering in January 2026 [15][8] - The company anticipates that the proceeds from recent financing will extend its cash runway into Q4 2026, potentially into Q2 2027 if warrants are exercised [15][8]

Core Viewpoint - Ocugen, Inc. has appointed Rita Johnson-Greene as Chief Financial Officer, marking a significant leadership change as the company prepares for transformative developments, including the submission of its first Biologics License Application this year [1][2]. Company Overview - Ocugen, Inc. is a biotechnology leader focused on gene therapies for blindness diseases, utilizing a novel modifier gene therapy platform that addresses complex diseases caused by imbalances in multiple gene networks [4]. - The company is developing programs for inherited retinal diseases and blindness diseases affecting millions globally, including retinitis pigmentosa, Stargardt disease, and geographic atrophy [4]. Leadership Background - Rita Johnson-Greene brings over 20 years of healthcare experience, having previously served as Chief Operating Officer at the Alliance for Regenerative Medicine, where she led operations and finance initiatives [2]. - Her prior roles include Vice President of Sales at Genetix Biotherapeutics, where she supported the launch of gene therapy brands, and senior leadership positions at Spark Therapeutics [2]. - Johnson-Greene holds an MBA in Finance and Strategic Management from The Wharton School and an undergraduate degree in Electrical Computer Engineering from Drexel University [3].

Core Viewpoint - Ocugen, Inc. has announced the pricing of an underwritten offering of 15 million shares of common stock at $1.50 per share, aiming for gross proceeds of $22.5 million, expected to close around January 22, 2026 [1]. Group 1: Offering Details - The offering consists of 15,000,000 shares priced at $1.50 each, resulting in gross proceeds of $22.5 million before expenses [1]. - The offering is led by RTW Investments, with participation from both new and existing investors [1]. - Oppenheimer & Co. is the sole book-running manager for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for general corporate purposes, capital expenditures, working capital, and general and administrative expenses [2]. Group 3: Company Overview - Ocugen, Inc. is a biotechnology leader focused on gene therapies for blindness diseases, with a modifier gene therapy platform aimed at addressing significant unmet medical needs [5]. - The company is developing programs for inherited retinal diseases and blindness diseases, including retinitis pigmentosa, Stargardt disease, and geographic atrophy [5].

Core Insights - Ocugen, Inc. is hosting a conference call and live webcast to discuss data from the OCU410 Phase 2 ArMaDa clinical trial, focusing on patients who have completed one year since treatment [1] - The conference call is scheduled for January 15, 2026, at 8:30 a.m. ET, featuring key opinion leaders and Ocugen's executive leadership [1][2] Company Overview - Ocugen, Inc. is a biotechnology leader specializing in gene therapies for blindness diseases, utilizing a modifier gene therapy platform that addresses complex diseases caused by imbalances in multiple gene networks [3] - The company is developing therapies for inherited retinal diseases and blindness diseases, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, which affect millions globally [3]

Core Insights - Ocugen, Inc. announced positive Phase 1 GARDian1 trial results for OCU410ST, a novel modifier gene therapy for Stargardt disease, published in the peer-reviewed journal Nature Eye [1][2] Group 1: Clinical Trial Results - The Phase 1 GARDian1 trial demonstrated robust efficacy and safety outcomes, indicating a favorable safety and tolerability profile for OCU410ST [3][4] - Among six patients with gradable Fundus Auto Fluorescence images, atrophic lesion growth was reduced by 54% in treated eyes compared to untreated eyes over 12 months [5] - Treated eyes showed a 50% slower lesion expansion rate compared to untreated eyes, below published natural history rates [5] - Visual acuity improved in treated eyes, with a gain of +6 letters in Best Corrected Visual Acuity (BCVA) compared to a decline in untreated eyes [5] - No drug-related serious adverse events were reported during the trial [5] Group 2: Disease Background - Stargardt disease is the most common form of inherited macular degeneration, affecting over 100,000 individuals in the U.S. and Europe, characterized by progressive central vision loss [3][7] - Currently, there are no FDA-approved treatments for Stargardt disease, highlighting a critical unmet medical need [3][7] Group 3: Future Developments - The ongoing Phase 2/3 GARDian3 trial is progressing ahead of schedule, with anticipated enrollment completion in the first quarter of 2026 [4] - The company plans to file a Biologics License Application (BLA) in the first half of 2027, aiming for three regulatory submissions within three years [4] Group 4: Technology Overview - OCU410ST utilizes an AAV5 delivery platform to deliver the RORA gene to the retina, addressing multiple pathophysiological pathways linked to Stargardt disease [6] - The therapy aims to provide a gene-agnostic modification strategy that could benefit patients regardless of their underlying ABCA4 mutation [4][6] Group 5: Company Overview - Ocugen, Inc. focuses on discovering and developing novel gene therapies for blindness diseases, aiming to address significant unmet medical needs through innovative approaches [8]

Core Insights - Ocugen is progressing with its late-stage modifier gene therapies, targeting BLA/MAA filings in 2026 and 2027, with significant enrollment milestones achieved in ongoing clinical trials [2][3][4] Clinical Development - The OCU400 Phase 3 liMeLiGhT clinical trial is nearing completion, with 50% enrollment achieved, and is on track for BLA and MAA submissions in 2026 [3][6] - The OCU410ST Phase 2/3 GARDian3 pivotal confirmatory trial is also progressing well, with the EMA accepting a single U.S.-based trial for MAA submission [4][6] - Ocugen's gene-agnostic approach aims to treat retinitis pigmentosa (RP), which affects approximately 300,000 individuals in the U.S. and Europe, with a single therapeutic method addressing multiple genetic mutations [3][12] Licensing and Financial Agreements - Ocugen has entered an exclusive licensing agreement with Kwangdong Pharmaceutical for OCU400 in South Korea, which includes potential upfront and milestone payments totaling up to $7.5 million, plus sales milestones projected to reach $180 million in the first decade [2][6] - The company will receive a 25% royalty on net sales from Kwangdong and is responsible for manufacturing and supplying OCU400 [2][6] Financial Performance - For Q3 2025, Ocugen reported total revenue of $1.75 million, an increase from $1.14 million in Q3 2024, while total operating expenses rose to $19.4 million from $14.4 million in the same period [10][19] - The net loss for Q3 2025 was $20.05 million, compared to a net loss of $12.97 million in Q3 2024 [19] - As of September 30, 2025, the company had cash and cash equivalents totaling $32.9 million, down from $58.8 million at the end of 2024 [12][19] Future Outlook - Upcoming milestones include the release of full data from the OCU410 Phase 2 trial in Q1 2026, interim data from the OCU410ST trial in mid-2026, and top-line data from the OCU400 Phase 3 trial in Q4 2026 [7][12] - The company is actively pursuing additional financing and strategic partnerships to support its commercialization efforts [7]

Core Viewpoint - Ocugen, Inc. has received a favorable opinion from the EMA's CHMP regarding the OCU410ST Phase 2/3 GARDian clinical trial for Stargardt disease, allowing a single U.S.-based trial for MAA submission, which could expedite marketing authorization in the EU [1][3]. Group 1: Clinical Trial Details - The ongoing pivotal confirmatory OCU410ST Phase 2/3 GARDian clinical trial aims to evaluate the treatment's effectiveness in slowing lesion growth and improving visual acuity in Stargardt disease patients [1][2]. - The trial will enroll 51 participants, with 34 receiving a one-time subretinal injection of OCU410ST and 17 in a control group, focusing on the reduction of atrophic lesion size as the primary objective [2][3]. - The Phase 1 GARDian trial demonstrated a 48% slower lesion growth and a statistically significant improvement in best corrected visual acuity (BCVA) at 12 months [2]. Group 2: Regulatory and Market Implications - The EMA's opinion is expected to reduce the time and cost for Ocugen to gain marketing authorization in the EU, aligning with the company's goal of filing three BLAs in the next three years [3]. - Recent milestones for the OCU410ST program include Rare Pediatric Disease Designation in May, IND clearance in June, and first patient dosing in July, with enrollment completion expected in Q1 2026 [3]. Group 3: About OCU410ST and Stargardt Disease - OCU410ST utilizes an AAV delivery platform to deliver the RORA gene, representing a modifier gene therapy approach targeting pathways linked to Stargardt disease [4]. - Stargardt disease is the most common form of inherited macular degeneration, leading to progressive vision loss due to the degeneration of photoreceptor cells in the retina [5][6].

Core Insights - Ocugen, Inc. is set to present at the 2025 BIO International Convention, showcasing its innovative gene therapies for blindness diseases [1][2] - The company has recently executed a binding term sheet for exclusive rights to OCU400 in Korea, indicating a strategic partnership aimed at enhancing its market presence [3] - Ocugen's modifier gene therapy platform has achieved significant milestones, including FDA alignment for a pivotal trial and nearing completion of enrollment for the OCU400 Phase 3 clinical trial, with plans to file a Biologics License Application by mid-2026 [3] Company Overview - Ocugen, Inc. specializes in gene therapies for blindness diseases, focusing on inherited retinal diseases and conditions affecting millions globally, such as retinitis pigmentosa and Stargardt disease [6] - The company's modifier gene therapy platform is designed to address complex diseases caused by imbalances in multiple gene networks, distinguishing it from traditional gene therapies [6] Conference Details - Dr. Shankar Musunuri, Chairman and CEO, will present on June 16, 2025, and participate in panel discussions on optimizing clinical outcomes and navigating the regulatory landscape during the convention [4][5]